Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of NRIX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Nurix Therapeutics, Inc. stock price down 3.61% on Tuesday
(Updated on Apr 30, 2024)

Sell candidate since Apr 19, 2024 Loss -11.55% PDF

The Nurix Therapeutics, Inc. stock price fell by -3.61% on the last day (Tuesday, 30th Apr 2024) from $12.47 to $12.02. During the last trading day the stock fluctuated 4.87% from a day low at $11.90 to a day high of $12.48. The price has fallen in 6 of the last 10 days and is down by -17.95% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -35 thousand shares and in total, 767 thousand shares were bought and sold for approximately $9.22 million.

Given the current short-term trend, the stock is expected to rise 49.48% during the next 3 months and, with a 90% probability hold a price between $17.97 and $28.40 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

NRIX Signals & Forecast

There are few to no technical positive signals at the moment. The Nurix Therapeutics, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $12.95 and $14.08. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, April 09, 2024, and so far it has fallen -31.24%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Nurix Therapeutics, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $10.55 and $10.20. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Nurix Therapeutics, Inc. finds support just below today's level at $10.55. If this is broken, then the next support from accumulated volume will be at $10.20 and $10.04.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.580 between high and low, or 4.87%. For the last week, the stock has had daily average volatility of 5.72%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (NRIX) For The Upcoming Trading Day Of Wednesday 1st

For the upcoming trading day on Wednesday, 1st we expect Nurix Therapeutics, Inc. to open at $12.13, and during the day (based on 14 day Average True Range), to move between $10.88 and $13.16, which gives a possible trading interval of +/-$1.14 (+/-9.49%) up or down from last closing price. If Nurix Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 18.98% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $12.36 (2.83%) than the support at $10.55 (12.23%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Nurix Therapeutics, Inc. stock A Buy?

The Nurix Therapeutics, Inc. stock holds several negative signals and despite the positive trend, we believe Nurix Therapeutics, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -1.327 Sell Candidate Unchanged

Predicted Opening Price for Nurix Therapeutics, Inc. of Wednesday, May 1, 2024

Fair opening price May 1, 2024 Current price
$12.13 ( 0.94%) $12.02

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for NRIX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 12.71 5.77 %
R2 12.49 3.92 %
R1 12.35 2.79 %
Current price: 12.02
Support S1 11.91 -0.90 %
S2 11.77 -2.04 %
S3 11.55 -3.88 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 14.13 17.55 %
R2 13.08 8.82 %
R1 12.36 2.83 %
Current price 12.02
Support S1 10.55 -12.23%
S2 10.20 -15.14%
S3 10.04 -16.47%

FAQ

What is the symbol for Nurix Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Nurix Therapeutics, Inc. is NRIX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Nurix Therapeutics, Inc. Stock?
The Nurix Therapeutics, Inc. stock holds several negative signals and despite the positive trend, we believe Nurix Therapeutics, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Nurix Therapeutics, Inc. Stock?
Nurix Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Nurix Therapeutics, Inc. Stock.

What's the current price of Nurix Therapeutics, Inc. Stock?
As of the end of day on the Apr 30, 2024, the price of an Nurix Therapeutics, Inc. (NRIX) share was $12.02.

What is the 52-week high and low for Nurix Therapeutics, Inc. Stock?
The 52-week high for Nurix Therapeutics, Inc. Stock is $18.12 and the 52-week low is $4.22.

What is the market capitalization of Nurix Therapeutics, Inc. Stock?
As of the Apr 30, 2024, the market capitalization of Nurix Therapeutics, Inc. is 739.689M.

When is the next earnings date for Nurix Therapeutics, Inc.?
The upcoming earnings date for Nurix Therapeutics, Inc. is Jul 11, 2024.
Click to get the best stock tips daily for free!

About Nurix Therapeutics, Inc.

Nurix Therapeutics. Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malig... NRIX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT